RxDoctor Payments Data

Edwin Chapman, MD

Internal Medicine · Washington, DCNPI 1841303880

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,623 of the $16,209 with a category attached, or 77.9%. Braeburn Inc. accounts for 95.7% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $15,478, more than ten times the $123 reported in 2019. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,209in general payments, 2019–2025

Across 77 payments — averaging $210.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$16K
  • Indivior Inc.$377
  • Orexo US, Inc.$84
  • Pfizer$49
  • Novo Nordisk$47
  • Lilly USA, LLC$36
  • plus $100 from 5 others

What the payments were for

  • Speaking & faculty fees$12,62378%
  • Travel & lodging$2,04413%
  • Food & beverage$1,54210%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,209 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$93,922
Medicare patients
76
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl1,234$783,379
BrixadiBuprenorphine28$50,235
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl259$46,180
OzempicSemaglutide15$14,297
Irbesartan43$1,035
Atorvastatin Calcium113$939
Amlodipine Besylate110$643
Nifedipine ErNifedipine13$591
Rosuvastatin Calcium34$457
Hydrochlorothiazide78$380
Valsartan14$318
Famotidine12$259
ClopidogrelClopidogrel Bisulfate23$249
Gabapentin28$218
Losartan Potassium26$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$377$783,3791,234 claims
Braeburn Inc.Brixadi$15,516$50,23528 claims
Novo NordiskOzempic$47$14,29715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →